I reiterate my own guidance price and am still not optimistic about an immediate reward form my purchases, but over the next year I think we can get there.
As indicated previously in the comment feed, I expect the multiple to compress which it has to around PE x15.97.
With NPBT of $4m approx. It leaves us with at MOST $3m NPAT.
Outstanding shares 116m = 0.025cents EPS x current P/E x15.97 gives us an approx. share price off $0.41c maybe 10% upside from here.
If we maintain this price right now, perhaps a little closer to the above, then we are currently at a reasonable valuation based on the downtrend in performance.
My reasoning is focused on FY 26 if we can grow underlying earnings to the $4m NPAT then that is where I expect a rerate and if the multiple increases in line with a conservative average say x17 (The 5 year average P/E of LBL is x21.23) then I expect a share price in 12-18 months of…
EPS 0.034 ($4m NPAT) x PE 18 = $0.586. around 50% upside.
*Given no dilution in the short term and they can at least grow earnings as guided initially.
I think now it is more likely, given that fact the Large US expansion strategy remains on hold, so expenditure isn’t as unpredictable, and we can capitalise on domestic growth.
The $1 valuation analysts are laying on this is very unreasonable, even as a shareholder I am not expecting this in the short term. There EPS extrapolation was ridiculous I think like 0.60c cents in another year. I don’t see how revenue and earnings can jump so much in a short time frame, and if it could where from?
- Forums
- ASX - By Stock
- LBL
- Ann: US Expansion Plans Temporarily On Hold
LBL
laserbond limited
Add to My Watchlist
0.00%
!
36.0¢

Ann: US Expansion Plans Temporarily On Hold, page-18
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
36.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.35M |
Open | High | Low | Value | Volume |
36.0¢ | 36.5¢ | 36.0¢ | $219.3K | 608.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49047 | 36.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 18685 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49047 | 0.360 |
5 | 79787 | 0.355 |
2 | 10132 | 0.350 |
2 | 30030 | 0.345 |
6 | 21741 | 0.340 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 14354 | 1 |
0.370 | 11746 | 2 |
0.380 | 75000 | 2 |
0.385 | 60000 | 2 |
0.390 | 43000 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
LBL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online